Tacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosis

INTERVENTION: group A:intravenous CTX 0.5‐0.75g/m2 Monthly+Oral prednisone (Prednisolone) 0.8mg/kg.d ;group B:Oral FK506 FK506 0.1mg/kg.d+prednisone (Prednisolone) 0.5mg/kg.d ; CONDITION: primary focal segmental glomerulosclerosis PRIMARY OUTCOME: blood and urine routine examination;24‐hour urine protein;Serum lipid (Triglyceride, Cholesterol);Liver and kidney function;FK506 concentratio; INCLUSION CRITERIA: 1. Written informed consent; 2. Age 18‐75 years old(Including 18 and 75 years); 3. The clinical and renal biopsy confirmed diagnosis of steroid‐resistant and steroid‐dependent primary focal segmental glomerulosclerosis; steroid‐resistant: patients who received prednisone or prednisolone(1mg/kg/d) treatment for 12 weeks did not remissionsteroid‐dependent: patients relapse when reducted to a certain dose of prednisone; 4. 24h urine protein> 1.5 g, and GFR> 30ml/min.; 5. Those who have not used other than in addition to glucocorticoid immunosuppressant or be discontinued for 3 months; 6. Blood pressure can be controlled over 135/85mmHg.